Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCU siRNA is a small interfering RNA designed to silence the expression of the Mitochondrial Calcium Uniporter (MCU), a protein complex responsible for the uptake of calcium into the mitochondria. In the context of acute myeloid leukemia (AML), research has shown that venetoclax-resistant leukemia stem cells (LSCs) upregulate calcium signaling and rely on high mitochondrial calcium levels to drive oxidative phosphorylation (OXPHOS). By targeting MCU with siRNA, researchers can reduce mitochondrial calcium levels, suppress calcium-dependent TCA cycle activity, and impair the survival and function of these resistant LSCs. This approach is being explored as a therapeutic strategy to overcome venetoclax resistance in AML.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MCU siRNA.